LinkedIn Profile

Access Catalyst Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:cprx 606814 Mar 24th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.1K 143.00 Open Mar 24th, 2024 12:24AM Mar 24th, 2024 12:24AM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 23rd, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.1K 143.00 Open Mar 22nd, 2024 11:21PM Mar 23rd, 2024 06:35PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 22nd, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.1K 143.00 Open Mar 21st, 2024 11:16PM Mar 22nd, 2024 06:23PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 21st, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.1K 143.00 Open Mar 20th, 2024 11:28PM Mar 21st, 2024 05:07PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 20th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.0K 143.00 Open Mar 19th, 2024 11:37PM Mar 20th, 2024 07:07PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 19th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.0K 143.00 Open Mar 18th, 2024 11:03PM Mar 19th, 2024 05:39PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 18th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.0K 143.00 Open Mar 17th, 2024 11:25PM Mar 18th, 2024 06:51PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 17th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.0K 143.00 Open Mar 17th, 2024 12:19AM Mar 17th, 2024 12:19AM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 16th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.0K 143.00 Open Mar 15th, 2024 10:55PM Mar 16th, 2024 06:39PM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:cprx 606814 Mar 15th, 2024 12:00AM Catalyst Pharmaceuticals, Inc. 9.0K 143.00 Open Mar 14th, 2024 11:54PM Mar 15th, 2024 08:28AM About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Open Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease Open 355 Alhambra Circle Coral Gables Florida US 33134 Catalyst Pharmaceuticals Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.